|
1
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Klaveren RJ, van’t Westeinde SC, de
Hoop BJ and Hoogsteden HC: Stem cells and the natural history of
lung cancer: implications for lung cancer screening. Clin Cancer
Res. 15:2215–2218. 2009.PubMed/NCBI
|
|
4
|
Sullivan JP, Minna JD and Shay JW:
Evidence for self-renewing lung cancer stem cells and their
implications in tumor initiation, progression, and targeted
therapy. Cancer Metastasis Rev. 29:61–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim CF, Jackson EL, Woolfenden AE,
Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT and Jacks T:
Identification of bronchioalveolar stem cells in normal lung and
lung cancer. Cell. 121:823–835. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosen JM and Jordan CT: The increasing
complexity of the cancer stem cell paradigm. Science.
324:1670–1613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao P, Lu Y, Jiang X and Li X:
Clinicopathological significance and prognostic value of CD133
expression in triple-negative breast carcinoma. Cancer Sci.
102:1107–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S and Gu J: CD133
positive hepatocellular carcinoma cells possess high capacity for
tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giangreco A, Groot KR and Janes SM: Lung
cancer and lung stem cells: strange bedfellows? Am J Respir Crit
Care Med. 175:547–553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng X, Li M, Wang X, Wang Y and Ma D:
Both CD133+ and CD133− subpopulations of A549
and H446 cells contain cancer-initiating cells. Cancer Sci.
100:1040–1046. 2009.
|
|
15
|
Qiu X, Wang Z, Li Y, Miao Y, Ren Y and
Luan Y: Characterization of sphere-forming cells with stem-like
properties from the small cell lung cancer cell line H446. Cancer
Lett. 323:161–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akunuru S, James Zhai Q and Zheng Y:
Non-small cell lung cancer stem/progenitor cells are enriched in
multiple distinct phenotypic subpopulations and exhibit plasticity.
Cell Death Dis. 3:e3522012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.PubMed/NCBI
|
|
18
|
Herpel E, Jensen K, Muley T, Warth A,
Schnabel PA, Meister M, Herth FJ, Dienemann H, Thomas M and
Gottschling S: The cancer stem cell antigens CD133, BCRP1/ABCG2 and
CD117/c-KIT are not associated with prognosis in resected
early-stage non-small cell lung cancer. Anticancer Res.
31:4491–4500. 2011.PubMed/NCBI
|
|
19
|
Shien K, Toyooka S, Ichimura K, Soh J,
Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, et al:
Prognostic impact of cancer stem cell-related markers in non-small
cell lung cancer patients treated with induction chemoradiotherapy.
Lung Cancer. 77:162–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cortes-Dericks L, Galetta D, Spaggiari L,
Schmid RA and Karoubi G: High expression of octamer-binding
transcription factor 4A, prominin-1 and aldehyde dehydrogenase
strongly indicates involvement in the initiation of lung
adenocarcinoma resulting in shorter disease-free intervals. Eur J
Cardiothorac Surg. 41:e173–e181. 2012. View Article : Google Scholar
|
|
21
|
Woo T, Okudela K, Mitsui H, Yazawa T,
Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H and Masuda M:
Prognostic value of CD133 expression in stage I lung
adenocarcinomas. Int J Clin Exp Pathol. 4:32–42. 2010.PubMed/NCBI
|
|
22
|
Li F, Zeng H and Ying K: The combination
of stem cell markers CD133 and ABCG2 predicts relapse in stage I
non-small cell lung carcinomas. Med Oncol. 28:1458–1462. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ettinger DS, Akerley W, Borghaei H, et al:
Non-Small Cell Lung Cancer, Version 2.2013. J Natl Compr Canc Netw.
11:645–653. 2013.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
25
|
Zeppernick F, Ahmadi R, Campos B, Dictus
C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and
Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in
glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sullivan JP, Spinola M, Dodge M, Raso MG,
Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et
al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma
stem cells dependent on notch signaling. Cancer Res. 70:9937–9948.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nichols J, Zevnik B, Anastassiadis K, Niwa
H, Klewe-Nebenius D, Chambers I, Schöler H and Smith A: Formation
of pluripotent stem cells in the mammalian embryo depends on the
POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ,
Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations
of Oct-4 and Nanog in oral cancer stem-like cells and high-grade
oral squamous cell carcinoma. Clin Cancer Res. 14:4085–4095. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK,
Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH and Chiou SH:
Oct-4 expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
